Novel SARS-COV-2/COVID-19: an update of prevalence, modes of transmission, clinical manifestations, prevention and management

Yıl 2021, Cilt: 2 Sayı: 3, 1 - 5, 30.08.2021

Yasmeen Junejo , Mehmet Özaslan , Muhammad Safdar

Öz

A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated with human to human transmission and extreme human sickness has been as of late announced from the city of Wuhan in China. This epidemic had spread to 210 countries and territories around the world with 6,049,380 confirmed cases, including 367,230 deaths, as of May 30, 2020, so the World Health Organization declared it as a Public Health Emergency of worldwide. It can cause serious respiratory diseases along with enteric, heart and neurological diseases, especially in immunocompromised patients. The reported symptoms include fever, coughing, sore throat, fatigue, headache, diarrhea, hemoptysis. trouble breathing, blue lips or face, persistent pain or pressure in the chest, confusion and excessive drowsiness. Preventive measures such as masks, frequent hand washing, staying home when sick, avoid public contact, and quarantines are being recommended for reducing the transmission. To date, no specific antiviral treatment is proven yet. There is a need to increase the knowledge of health care professionals regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, control, and management. For this, they must know about the prevalence, clinical manifestation, modes of transfer, control measures and management, etc. There must be a special task force that considers raising public awareness in the regions where the virus attacks. They must guide the people with the signs and symptoms of the disease.

Anahtar Kelimeler

COVID-19, SARS-CoV-2, Preventive Measures, review

Kaynakça

• 1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001316.
• 2. Wang C, Wang X. Prevalence, nosocomial infection and psychological prevention of novel coronavirus infection. Chin General Pract Nurs. 2020;18:2–3.
• 3. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD: Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls Publishing, Treasure Island, FL; 2020.
• 4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
• 5. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China—key questions for impact assessment. N Engl J Med. 2020; 382: 692-694.
• 6. van Doremalen N, Morris D, Bushmaker T et al. Aerosol and Surface Stability of SARS-CoV-2 as compared with SARSCoV-1. New Engl J Med 2020 doi: 10.1056/NEJMc2004973.
• 7. Mehmet Ozaslan, Muhamad Safdar, I. Halil Kilic and Rozhgar A. Khailany, 2020. Practical Measures to Prevent COVID-19: A Mini-Review. Journal of Biological Sciences, 20: 100-102.
• 8. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14: 523-534.
• 9. Liu J, Liao X, Qian S et al. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis 2020 doi.org/10.3201/eid2606.200239
• 10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
• 11. Wei Q, Ren Z. Disinfection measures for pneumonia foci infected by novel coronavirus in 2019. Chin J Disinfect. 2020;37:59–62.
• 12. Ou F, Wu H, Yang Y, Tan W, Zhang J, Gu J. Countermeasures for rapid spread of new coronavirus pneumonia in Wuhan. Chin General Pract Nurs. 2020. http://kns.cnki.net/kcms/detail/14.1349.R.20200131.1319.002.html.
• 13. Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, Gin T, Chan MTV. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur. Respir. J. 2019 Apr;53(4).
• 14. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem. 2020 Feb 24.
• 15. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl. Acad. Sci. U.S.A. 2020 Feb 13.
• 16. Luo H, Tang Q-L, Shang Y-X, Liang S-B, Yang M, Robinson N, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020.
• 17. Burke RM, Midgley CM, Dratch A, Fenstersheib M, Haupt T, Holshue M,et al. Active monitoring of persons exposed to patients with confirmed COVID-19 — United States, January–February 2020. MMWR Morb Mortal Wkly Rep. 2020 doi : 10.15585/mmwr.mm6909e1external icon.
• 18. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 February 2020 [Internet]. Geneva: World Health Organization; 2020 Available from: https://www.who.int/docs/defaultsource/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.
• 19. Ong SW, Tan YK, Chia PY, Lee TH, Ng OT, Wong MS, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020 Mar 4.
• 20. Li T, Wei C, Li W, Hongwei F, Shi J. Beijing Union Medical College Hospital on "pneumonia of novel coronavirus infection" diagnosis and treatment proposal (V2.0). Med J Peking Union Med Coll Hosp. 2020. http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html.
• 21. Khailany, R.A.; Safdar, M.; Ozaslan, M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020, 19, 1–6.